Nexviazyme Market Report 2026

Nexviazyme Market Overview

• The Nexviazyme market growth in the historic period has been driven by established diagnosis of pompe disease, availability of enzyme replacement platforms • Market expansion is supported by increasing investments in orphan drug development, rising demand for improved patient outcomes • Growth Driver: Rising Prevalence Of Pompe Disease To Drive Growth In The Market • Market Trend: Regulatory Approval Propels Nexviazyme As A Breakthrough Therapy For Late-Onset Pompe Disease • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Nexviazyme Market?

Nexviazyme is a medication designed for the treatment of pompe disease, a rare genetic disorder that affects muscle and respiratory function. It is a biological therapy developed to address the underlying cause of the disease by replacing the missing or deficient enzyme, acid alpha-glucosidase (GAA), to help improve muscle strength and respiratory function in patients. The main indication types of nexviazyme are infantile-onset pompe disease and late-onset pompe disease. Infantile-onset pompe disease is a rare genetic disorder that appears in infants, typically within the first few months of life. The distribution channels are hospital pharmacies, retail pharmacies, and online pharmacies, and they are used by various end users such as adults, pediatrics, and geriatrics.

What Is The Nexviazyme Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in orphan drug development, rising demand for improved patient outcomes, expansion of newborn screening initiatives, advancements in recombinant enzyme technologies, growing focus on long-term disease management. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, growing focus on rare genetic disorder treatments, expansion of specialized infusion-based care, rising emphasis on early diagnosis of pompe disease, enhanced development of long-acting biologics.

Global Nexviazyme Market Segmentation

1) By Indication: Infantile-Onset Pompe Disease, Late-Onset Pompe Disease 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Adult, Pediatric, Geriatric

What Is The Driver Of The Nexviazyme Market?

The increasing prevalence of pompe disease is expected to drive the nexviazyme market going forward. Pompe disease is a rare genetic disorder caused by a deficiency of the enzyme acid alpha-glucosidase, leading to the buildup of glycogen in muscles, which causes progressive muscle weakness and respiratory issues. The increasing prevalence of pompe disease can be attributed to advancements in diagnostic technologies, such as genetic screening and newborn screening programs. Nexviazyme is used as an enzyme replacement therapy to treat late-onset pompe disease by reducing glycogen buildup in muscles, improving respiratory function, and improving mobility. For instance, in December 2024, according to a report published by the International Brain Research Organization, a France-based federation of neuroscience organizations, the global birth prevalence of Pompe disease was noted to be 2.0 cases per 100,000 live births. Moreover, the prevalence of infantile-onset Pompe disease was 1.0 cases per 100,000 live births, while late-onset Pompe disease had a prevalence of 2.4 cases per 100,000 live births. Therefore, the increasing prevalence of Pompe disease drives the nexviazyme industry.

Key Players In The Global Nexviazyme Market

Major companies operating in the nexviazyme market are Sanofi S.A.

Global Nexviazyme Market Trends and Insights

The key trend in the nexviazyme market is the development of new treatment options for patients aged one year and older with late-onset Pompe disease. Nexviazyme, an enzyme replacement therapy (ERT), is designed to target the mannose-6-phosphate (M6P) receptor, enhancing cellular enzyme uptake to treat late-onset Pompe disease, a progressive muscle disorder. For instance, the Food and Drug Administration (FDA), a US-based federal agency, approved Nexviazyme for patients aged one year and older with late-onset Pompe disease. Clinical trials demonstrated its ability to improve respiratory function and walking distance, establishing it as a transformative therapy in the treatment of rare diseases.

What Are Latest Mergers And Acquisitions In The Nexviazyme Market?

In May 2023, Sanofi, a France-based pharmaceutical company, partnered with Maze Therapeutics to advance its glycogen synthase 1 (GYS1) program and lead candidate MZE001 for Pompe disease. This could significantly improve patient outcomes by addressing the underlying causes of glycogen accumulation and potentially enhancing overall treatment efficacy. Maze Therapeutics is a US-based biotech company focused on developing precision medicines for rare genetic diseases.

Regional Insights

North America was the largest region in the nexviazyme market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Nexviazyme Market?

The nexviazyme market consists of sales of nexviazyme Infusion pumps and intravenous (IV) tubing. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nexviazyme Market Report 2026?

The nexviazyme market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nexviazyme industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.